- CJC-1295 without DAC, also called Modified GRF (1-29), is a short-acting GHRH-receptor agonist used as a tool compound to study acute, pulsatile growth-hormone release.
- Human data on this compound is minimal and has not been analyzed by sex, so the dose conventions that circulate for it were not derived from female-specific research.
- Many indexed studies of GHRH-type signaling included female subjects but none reported sex-stratified outcomes for this analogue, leaving its behavior in women unstudied.
A lot of what circulates about the growth-hormone releasers is stated with more confidence than the data supports, and CJC-1295 without DAC is a clean example. It is a research tool for studying the somatotropic axis, its human record is thin, and the dose conventions people trade around it were not built on female-specific work. For a female-focused database, the useful move is to separate the mechanism, which is reasonably well defined, from the women's evidence, which is not.
Also known as Modified GRF (1-29), CJC-1295 without DAC is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone. It lacks the albumin-binding Drug Affinity Complex of its longer-acting counterpart, so it clears quickly and acts briefly. That short duration is the feature, not a flaw: it makes the molecule useful for probing the immediate, transient phase of GHRH signaling rather than sustained activation.
How it is studied to work
In endocrine and secretagogue research models, this analogue has been studied as a GHRH-receptor agonist, particularly for acute and pulsatile stimulation of growth-hormone release. Its rapid clearance lets investigators capture the sharp, time-resolved receptor events that a long-acting version would blur. It is supplied for in-vitro and laboratory research only.
The female evidence, stated plainly
Human data on CJC-1295 without DAC is minimal, and what exists has not been analyzed by sex. In the indexed literature on this class of signaling, many studies included female subjects, yet none reported sex-stratified outcomes for this analogue. So the women's evidence is unstudied across the board, and any dose or response figure that circulates should be understood as coming from male-weighted or sex-blind sources.
- Sex differences: unstudied; female subjects were present in some indexed work, but no sex-stratified outcomes were reported for this compound.
- Menstrual cycle: no cycle interaction data.
- Hormonal interactions: the growth-hormone axis interacts with estrogen in general, but no study characterizes this for CJC-1295 without DAC in women.
- Perimenopause and menopause: no data in perimenopausal or menopausal populations.
- Pregnancy and lactation: no pregnancy or lactation safety data.
Any dose figures associated with CJC-1295 without DAC are reported in research contexts only, and this compound has no established human dose. Nothing here is a protocol, an instruction, or medical advice, and this site does not publish personal dosing.
Why sex-blind dosing is a real limitation
Estrogen influences growth-hormone secretion, so the amount of a GHRH-receptor agonist that produces a given effect could differ between a female and a male body. When the underlying research did not stratify by sex, the numbers that get passed around inherit that blind spot. That is the quiet cost of a male-weighted evidence base: the conventions look precise, but they were never checked against female physiology. A convention is not a finding, and for this compound in women there is no finding to point to.
With no pregnancy or lactation safety data, CJC-1295 without DAC is not presented as safe in pregnancy, breastfeeding, or while trying to conceive. The absence of data is the finding.
CJC-1295 without DAC is a legitimate mechanistic tool with an honestly empty female record, and both halves of that sentence matter. You can review the full evidence breakdown, including every unstudied field, on the CJC-1295 without DAC profile.